Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A multinational multicenter open-label rater-blinded Phase II study.
Brief description of study
The purpose of this study is to investigate if the study drug N-Acetyl-L-Leucine, called IB1001, can help improve the symptoms of GM2 Gangliosidosis after 6-weeks of treatment. This will be compared to Baseline (before you started treatment with IB1001) and 6-weeks of post-treatment washout. The study will also look at how well patients tolerate taking IB1001. GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease) are rare, devastating, neurovisceral autosomal recessive, lysosomal storage disorders (LSD). GM2 Gangliosidosis can be classified into 3 variants: Tay-Sachs disease, Sandhoff disease and AB variant of Tay-Sachs disease
Clinical Study Identifier: s17-01666
ClinicalTrials.gov Identifier: NCT03759665
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
